 BOSTON, Oct. 01, 2021 GLOBE NEWSWIRE -- Ikena Oncology, Inc. Nasdaq: IKNA, a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three abstracts highlighting the companys Aryl Hydrocarbon Receptor AHR antagonist program, with novel inhibitor IK-175, will be presented at the SITC 2021 Annual Meeting. IK-175 is an oral AHR antagonist designed to modulate the tumor microenvironment to increase both innate and adaptive immunity and is currently being studied in a Phase 1 clinical trial . 